ACRV Acrivon Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
18:16
Jan 13
Jan 13
Lilly's interest in ACRV drug, oversold
The author argues that Eli Lilly's retained financial interest in Acrivon's ACR-368 (prexasertib), including potential milestone payments, royalties, and a contractual right to negotiate first to reacquire the drug, makes ACRV an attractive oversold opportunity. The mechanism is that Lilly's vested interest could lead to a buyout or reacquisition, providing upside. No specific timeframe or risk is stated.
MED
18:32
Jan 06
Jan 06
ACRV short squeeze setup with high short interest and Buy catalyst
The author argues ACRV is set up for a short squeeze because about 17.7% of the float is sold short and days to cover exceed 10 days, while effective float is constrained by insider/institutional ownership. The stated catalyst is H.C. Wainwright initiating coverage with a Buy rating and a $19 price target, which could bring buying that forces shorts to cover and creates a reflexive loop of rising prices and covering. The main stated downside is gradual erosion, while upside is a sharp accelerated move if shorts are squeezed.
HIGH
About ACRV Investor Commentary
Across the available history and selected sources, Buzzberg tracks ACRV (Acrivon Therapeutics, Inc.) across 1 sources: 2 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: u/Choice_Client_5400, u/Mundane-Concept-2185.